Creo Medical Group PLC
LSE:CREO
Creo Medical Group PLC
LSE:CREO
Price:
13.51
GBX
-1.75%
Market Cap:
£55.7m
Relative Value
The Relative Value of one
CREO
stock under the Base Case scenario is
1.81
GBX.
Compared to the current market price of 13.51 GBX,
Creo Medical Group PLC
is
Overvalued by 87%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
CREO
Relative Value
Base Case
1.81
GBX
Overvaluation 87%
Multiples Across Competitors
CREO Competitors Multiples
Creo Medical Group PLC Competitors
Creo Medical Group PLC Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| UK |
|
Creo Medical Group PLC
LSE:CREO
|
55.7m GBP | 25.3 | 3.3 | -4.2 | -3.7 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
187.6B USD | 4.2 | 28.8 | 16.5 | 22.6 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
167.7B USD | 16.7 | 58.7 | 44.5 | 54.7 | |
| US |
|
Stryker Corp
NYSE:SYK
|
128.8B USD | 5.1 | 39.7 | 20.3 | 24.5 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
111.8B USD | 3.2 | 24.2 | 13.4 | 19.5 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
102.5B USD | 5.1 | 35.4 | 20.8 | 27.9 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
43.3B EUR | 1.9 | 20.5 | 11.4 | 16.1 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.5B USD | 7.8 | 44.3 | 24.4 | 26.7 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.7B USD | 10.6 | 43.2 | 30.6 | 33.9 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
45.4B USD | 2.1 | 25.8 | 10.2 | 17.2 | |
| US |
|
Resmed Inc
NYSE:RMD
|
33.6B USD | 6.2 | 22.6 | 15.9 | 17.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
